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Recent evidence suggests that Runt-related transcription factors play a role in different human tumours. In the present study, the
localisation of the Runt-related transcription factor-2 (Runx2), its transcriptional activity, as well as its regulation of expression was
analysed in human pancreatic ductal adenocarcinoma (PDAC). Quantitative real-time PCR and immunohistochemistry were used for
Runx2 expression and localisation analysis. Runt-related transcription factor-2 expression was silenced using specific siRNA
oligonucleotides in pancreatic cancer cells (Panc-1) and immortalised pancreatic stellate cells (IPSCs). Overexpression of Runx2 was
achieved using a full-length expression vector. TGF-b1, BMP2, and other cytokines were assessed for their potential to regulate
Runx2 expression. There was a 6.1-fold increase in median Runx2 mRNA levels in PDAC tissues compared to normal pancreatic
tissues (Po0.0001). Runt-related transcription factor-2 was localised in pancreatic cancer cells, tubular complexes, and PanIN lesions
of PDAC tissues as well as in tumour-associated fibroblasts/stellate cells. Coculture of IPSCs and Panc-1 cells, as well as treatment
with TGF-b1 and BMP2, led to increased Runx2 expression in Panc-1 cells. Runt-related transcription factor-2 overexpression was
associated with decreased MMP1 release as well as decreased growth and invasion of Panc-1 cells. These effects were reversed by
Runx2 silencing. In conclusion, Runx2 is overexpressed in PDAC, where it is regulated by certain cytokines such as TGF-b1 and BMP2
in an auto- and paracrine manner. In addition, Runx2 has the potential to regulate the transcription of extracellular matrix modulators
such as SPARC and MMP1, thereby influencing the tumour microenvironment.
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Runt-related transcription factor-2 (Runx2, also known as core-
binding factor, runt domain, a-subunit 1, CBFA1, AML3, or OSF2)
is the human homologue of mouse PEBP2A and acts as an
osteoblast-specific transcription factor (Ogawa et al, 1993;
Levanon et al, 1994). Runt-related transcription factor-2 has been
isolated from haematopoietic cells and has a close homology to
Runx1 and Runx3 (Ogawa et al, 1993). During embryonic
development, Runx2 controls bone cell differentiation, and after
birth, Runx2 controls bone matrix deposition, especially collagen I,
by differentiated osteoblasts (Ducy et al, 1999). Homozygous
Runx2 mutations are lethal perinatal (Komori et al, 1997), and
altered chondrocyte morphology is observed in Runx2 hetero-
zygous mice (Zheng et al, 2003). Runt-related transcription factor-
2 acts as a scaffold that controls the integration, organisation, and
assembly of regulatory factors for skeletal gene expression (Stein
et al, 2004). Thus, Runx2 mutations cause cleidocranial and teeth
dysplasia and altered endochondral ossification (Mundlos et al,
1997; D’Souza et al, 1999). This occurs via altered Runx2
regulation of hypertrophic chondrocyte-specific genes (Yoshida
et al, 2004). In contrast, overexpression of Runx2 enhances
osteoclast differentiation in vitro and bone resorption in vivo, and
leads to overexpression of Rankl and collagenase-3 (MMP13)
(Geoffroy et al, 2002).
Runt-related transcription factor-2 transcriptional activity is
regulated by multiple pathways, such as the MAPK, PI3K, and
STAT pathways (Lee et al, 2002; Xiao et al, 2002; Fujita et al, 2004).
Runt-related transcription factor-2 also regulates several down-
stream target genes, such as extracellular matrix proteins, growth
factors and receptors, mitochondrial proteins, and transcription
factors (Gaikwad et al, 2001).
Runt-related transcription factor-2 regulation and transcrip-
tional activity are linked with increased growth, invasion,
and metastasis in breast cancer (Barnes et al, 2003), prostate
cancer (Brubaker et al, 2003; Pratap et al, 2005), colorectal
cancer (Wai et al, 2006), lymphoma, leukaemia and myeloma
(Wotton et al, 2002; Castilla et al, 2004; Colla et al, 2005; Blyth
et al, 2006).
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(Guweidhi et al, 2005), MMP1 (Gress et al, 1995), IBSP (Kayed
et al, 2006), and SPP1 (Kolb et al, 2005), have been shown to play a
role in pancreatic carcinogenesis. In addition, a number of growth
factors that have the potential to regulate Runx2 expression also
play a role in pancreatic carcinogenesis, such as TGF-b1 (Friess
et al, 1993a,b; Yamanaka et al, 1993), BMP2 (Kleeff et al, 1999),
and IHH (Kayed et al, 2004). Therefore, in the present study the
localisation, transcriptional activity, and regulation of Runx2
expression in human pancreatic ductal adenocarcinoma (PDAC)
was analysed.
PATIENTS AND METHODS
Tissue sampling
Pancreatic ductal adenocarcinoma (n¼17) and chronic pancrea-
titis (CP; n¼13) tissue specimens were obtained from patients in
whom pancreatic resections were performed. Normal human
pancreatic tissue samples (n¼16) were obtained through an
organ donor programme from previously healthy individuals. All
samples were confirmed histologically. Freshly removed tissues
were fixed in paraformaldehyde solution for 12–24h and then
paraffin embedded for histological analysis. In addition, a portion
of human pancreatic tissue samples was preserved in RNAlater
(Ambion Europe Ltd, Huntingdon, Cambridgeshire, UK), or snap-
frozen in liquid nitrogen immediately upon surgical removal and
maintained at  801C until use. The Human Subjects Committee of
the University of Heidelberg, Germany, approved all studies.
Written informed consent was obtained from all patients.
Quantitative real-time polymerase chain reaction
All reagents and equipment for mRNA/cDNA preparation were
supplied by Roche Applied Science (Mannheim, Germany). mRNA
of human pancreatic tissues was prepared by automated isolation
using the MagNA Pure LC Instrument and Isolation kit I (for cells)
and kit II (for tissues). cDNA was prepared using the First Strand
cDNA Synthesis kit for RT–PCR according to the manufacturer’s
instructions. The primer sequences for all genes were obtained
from Search-LC (Heidelberg, Germany). Real-time PCR was
performed using the LightCycler FastStart DNA SYBR Green kit.
The number of specific transcripts was normalised to house-
keeping genes (cyclophilin B and HPRT) and presented as adjusted
transcripts/ml cDNA, as described previously (Kayed et al, 2004).
Immunohistochemistry and immunocytochemistry
Paraffin-embedded tissue sections 2–3mm thick were deparaffi-
nised in xylene and rehydrated in progressively decreasing
concentrations of ethanol. Thereafter, the slides were placed in
washing buffer (10mM Tris-HCl, 0.85% NaCl, 0.1% bovine serum
albumin, pH 7.4) and subjected to immunostaining. Antigen
retrieval was performed by boiling tissue sections in 10mM citrate
buffer for 10min in a microwave oven. To confirm the specificity
of Runx2 staining, the sections were incubated with a rabbit
polyclonal (Sigma-Aldrich, St Louis, MO, USA), a goat polyclonal
(R&D Systems GmbH, Wiesbaden, Germany), or a rat monoclonal
Runx2 antibody (R&D Systems GmbH). The corresponding
normal IgGs were used as negative controls. The slides were then
rinsed with washing buffer and incubated with HRPO-conjugated
anti-rabbit (Amersham International, Buckinghamshire, UK), anti-
goat (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), or
anti-rat IgG (Amersham International), respectively, for 1h at
room temperature. Tissue sections were then washed in washing
buffer and DAB-chromogen/substrate mixture (DAKO, Hamburg,
Germany) was applied to each section. Slides were analysed using
the Axioplan 2 imaging microscope (Carl Zeiss Light Microscope,
Go ¨ttingen, Germany). For immunocytochemistry, immortalised
primary human pancreatic stellate cells (IPSCs) (Jesnowski et al,
2005) and Panc-1 cells were seeded on SuperFrost microscope
slides (Menzel GmbH & Co KG, Braunschweig, Germany)
overnight till adherent, and fixed with 3.5% paraformaldehyde
for 25min, and quenched with 30mM glycine/PBS for 5min.
Permeabilisation of the cell membrane was carried out with 0.1%
Triton X-100 for 5min at room temperature. Immunostaining was
then performed as described above using the goat polyclonal
Runx2 antibody (R&D Systems GmbH). Slides were analysed using
the Axioplan 2 imaging microscope (Carl Zeiss Light Microscope).
Cell culture
Panc-1 pancreatic cancer cells and IPSCs were routinely grown in
DMEM medium supplemented with 10% fetal calf serum (FCS) and
100Uml
 1 penicillin (complete medium), and incubated in a 5%
CO2 humid atmosphere. For induction experiments, cells were
seeded in 10cm cell culture plates in 10% FCS growth medium and
allowed to attach for 12h. Growth medium was replaced by serum-
reduced medium (1% FCS), and supplemented with recombinant
TGF-b1 (500pM), BMP2 (100ngml
 1), FGF2 (10ngml
 1), Shh
(500ngml
 1), Ihh (500ngml
 1) (R&D Systems GmbH) and TNF-a
(100ngml
 1) (Promega Biosciences Inc., Mannheim, Germany)
for 48h. The doses were determined to ensure the efficacy and
absent toxicity of each factor (Nakamura et al, 1997; Kleeff et al,
2000; Li et al, 2003; Kayed et al, 2004; Guo et al, 2006). Afterwards,
cell culture supernatants, cell lysates, and mRNA were isolated as
described. For coculture experiments without cell-to-cell contact,
Panc-1 cells as well as IPSCs were seeded in both the wells and
inserts of 12-well plates supplemented with permeable 0.4mm
polyester membranes (Sigma-Aldrich) for 48h.
siRNA transfection
Panc-1 cells and IPSCs were grown in complete DMEM medium in
10ml cell culture plates until 50% confluence. Runt-related
transcription factor-2 siRNA transfection was performed using
RNAiFect transfection reagent (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. Cells were transfected with
5mg siRNA (Runx2 target sequence AATGGCAGCACGCTAT
TAAAT) and control siRNA (target sequence AATTCTCC
GAACGTGTCACGT) (Qiagen) for 48h.
Transient transfection of pancreatic cancer and stellate
cells
The full-length cDNA encoding human Runx2 (pcDNA3.1/Runx2)
was kindly provided by LD Quarles (Department of Medicine,
Duke University Medical Center, Durham, NC, USA). Transient
transfection of Panc-1 cells and IPSCs with the pcDNA3.1/Runx2
vector was carried out using the Lipofectamine method (Life
Technologies, Karlsruhe, Germany) according to the manufac-
turer’s instructions. Briefly, cells were seeded in 10cm dishes in
complete cell culture medium until 50% confluence. The medium
was replaced by serum-free medium containing 5mg of pcDNA3.1/
Runx2 or empty vector in transfection mixture for 3h. An equal
volume of medium containing 20% FCS was added for 24h, and
then replaced by complete medium.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) kits were used for
determining MMP1 protein levels in cell culture supernatants
according to the manufacturer’s instructions (RayBiotech Inc.,
Ko ¨ln, Germany).
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Cells were washed twice with ice-cold PBS and lysed with lysis
buffer (50mM Tris-HCl, 100mM NaCl, 2mM EDTA, 1% SDS)
containing one tablet of complete mini-EDTA-free protease
inhibitor cocktail (Roche Applied Science). Protein concentration
for both cell lysates and supernatant was determined by the BCA
protein assay (Pierce Chemical Co, Rockford, IL, USA). Protein/
lane (20mg) were separated on SDS-polyacrylamide gels and
electroblotted onto nitrocellulose membranes. Membranes were
then incubated in blocking solution (5% non-fat milk in 20mM
Tris-HCl, 150mM NaCl, 0.1% Tween-20), followed by incubation
with a rabbit polyclonal Runx2 antibody or a mouse monoclonal
SPARC antibody (R&D Systems GmbH) at 41C overnight. The
membranes were washed and incubated with donkey anti-rabbit
(Santa Cruz Biotechnology Inc.) or anti-mouse HRPO-conjugated
IgG (Amersham International) for 1h at room temperature. Equal
loading and transfer was confirmed using a goat polyclonal
g-tubulin, or a rabbit polyclonal anti-ERK2 antibody (Santa Cruz
Biotechnology Inc.), and Ponceau S staining (Sigma-Aldrich).
Antibody detection was performed by an enhanced chemilumines-
cence reaction (Amersham International).
Cell growth assays
Cells were seeded at a density of 5000cellswell
 1 in 96-well plates
for 48h. Then, 10ml MTT (5mgml
 1) dissolved in PBS pH 7.4
were added to each well and incubated for 4h at 371C.
Subsequently, cellular formazan was solubilised with 0.04mM
HCl/isopropanol. Optical density was measured at 570nm with
an ELISA plate reader (Opsys MR, ThermoLabsystems, Frankfurt,
Germany). All assays were performed in triplicate.
In vitro invasion assays
The Matrigel invasion assay (BD Biosciences, Heidelberg, Germany)
was used to assess the invasive potential. Briefly, BioCoat Matrigel
invasion chambers were rehydrated according to the manufac-
turer’s instructions. Five hundred microlitres of DMEM cell culture
medium supplemented with 10% FCS was added to the bottom of
24-well plates. Cells were seeded at a density of 50000cellswell
 1
into the upper inserts and incubated at 371C. After 24h, the non-
invading cells were removed from the upper surface of the
separating membrane by gentle scrubbing with a cotton swab.
Invading cells were fixed in cold 100% methanol and stained with
0.05% crystal violet in 20% ethanol. The membranes were mounted
on glass slides and manually counted using a light microscope. The
invasion index was calculated as the percentage of invaded cells in
the treatment group compared to the control group. All assays
were performed in triplicate.
Statistical analysis
Results are expressed as the mean±s.e.m. unless indicated
otherwise. For statistical analysis, the non-parametric Mann–
Whitney test was used for all experiments. Significance was
defined as Po0.05.
RESULTS
Runx2 expression and localisation in pancreatic tissues
To exactly quantify the mRNA levels of Runx2, Quantitative real-
time polymerase chain reaction (QRT–PCR) was carried out in
bulk pancreatic tissues. This analysis demonstrated 10.7- and 6.1-
fold increases in median Runx2 mRNA levels in CP (Po0.01) and
PDAC (Po0.0001) tissues, respectively, compared to the normal
pancreas (Figure 1A). There was a 1.8-fold increase in median
Runx2 mRNA levels in CP compared to PDAC, but this was not
significant (P¼0.7). Correlation analysis of Runx2 mRNA expres-
sion with TNM staging of PDAC patients revealed a tendency for
decreased median Runx2 mRNA levels in PDAC patients with
lymph node metastasis compared to PDAC patients without lymph
node metastasis (P¼0.7; data not shown). There was no
correlation with other histopathological parameters. To localise
Runx2, immunohistochemistry was performed on pancreatic tissue
sections from normal (n¼10), CP (n¼5) and PDAC (n¼20)
cases. Runt-related transcription factor-2 expression was weak to
absent in normal pancreatic tissues. Specifically, acinar and ductal
cells were devoid of Runx2 expression (Figure 1B and C). In
contrast, in CP tissues there was moderate staining of the tubular
complexes (Figure 1D). Moderate Runx2 staining was also
observed in PanIN lesions (Figure 1E). Pancreatic cancer cells
were positive for Runx2 in 10 out of 20 cases and demonstrated
both cytoplasmic and nuclear staining (Figure 1F–H). Addition-
ally, there was moderate-to-strong Runx2 expression in the
fibroblasts within the desmoplastic stroma surrounding the cancer
cells in 11 out of 20 cases (Figure 1G inset). Three Runx2
antibodies were used in consecutive pancreatic tissue sections to
confirm the specificity of Runx2 immunoreactivity (Figure 1F–H).
The specificity of the staining was further confirmed using the
corresponding normal IgGs as negative controls (Figure 1H inset).
Effects of coculture between IPSCs and Panc-1 cells
As Runx2 was localised in the cancer cells and the associated
fibroblasts in PDAC tissues, next the effects of coculture with or
without direct cell-to-cell contact between Panc-1 cells and IPSCs
were analysed. Coculture experiments without cell-to-cell contact
revealed that soluble factors released from IPSCs were able to
increase Runx2 expression in Panc-1 cells. In contrast, factors
released from Panc-1 cells reduced Runx2 expression in IPSCs
(Figure 2A). On the other hand, coculture with cell-to-cell contact
between Panc-1 cells and IPSCs led to no significant difference in
the Runx2 staining intensity in Panc-1 cells or IPSCs as shown by
immunocytochemistry (Figure 2B).
Regulators of Runx2 expression in IPSCs and Panc-1 cells
Since Runx2 expression is regulated by factors released from both
pancreatic cancer cells and pancreatic stellate cells, we sought to
analyse the effects of different growth factors and cytokines on
Runx2 expression in these cells (Figure 2C). Interestingly,
members of the TGF-b family (TGF-b1 and BMP2) divergently
regulated Runx2 mRNA expression in Panc-1 cells and IPSCs.
Thus, TGF-b1 led to a mild reduction of Runx2 mRNA expression
in Panc-1 cells and IPSCs. In contrast, BMP2 increased Runx2
mRNA expression in Panc-1 cells but decreased Runx2 mRNA
expression in IPSCs (Figure 2C). Immunoblotting was carried out
to confirm these results at the protein level. Interestingly, both
TGF-b1 and BMP2 increased Runx2 protein levels in Panc-1 cells
(Figure 2C). In contrast, there was no significant change in Runx2
protein levels after treatment of IPSCs with TGF-b1 or BMP2.
Additionally, there was a significant reduction of Runx2 mRNA
expression in Panc-1 cells after FGF2 treatment by  35.7±4.2%
and Shh by  31.3±8.5% (Figure 2C). In IPSCs, there was also a
significant reduction of Runx2 mRNA expression after treatment
with FGF2 by  35.7±1.4%, TNF-a by  26.3±0.5%, and Shh by
 30±6.1% (Figure 2C).
Transcriptional targets of Runx2 in IPSCs and Panc-1 cells
The basal mRNA expression levels of Runx2 and target genes were
determined in Panc-1 cells and IPSCs by QRT–PCR (Figure 3A).
In the next set of experiments, the transcriptional activity of Runx2
was analysed in IPSCs and Panc-1 cells. Runt-related transcription
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molecules, resulting in reduction of Runx2 mRNA levels by
 37±6% in Panc-1 cells and  11±6% in IPSCs (Figure 3B).
There was a significant increase in SPARC and MMP1 mRNA levels
in Panc-1 cells of 60±9.2 and 14±4.2%, respectively. In IPSCs,
there was a significant increase in SPARC and MMP1 mRNA levels
by 19±1.2 and 10±3.2% respectively. At the protein level, there
was a significant upregulation of SPARC (data not shown) and
MMP1 (Figure 3C) following Runx2 silencing in the cell culture
supernatant of Panc-1 cells, but these changes were not significant
for IPSCs. The transcriptional activity of Runx2 was analysed after
transient Runx2 overexpression in Panc-1 cells and IPSCs using a
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Figure 1 (A) Runt-related transcription factor-2 mRNA expression levels in pancreatic tissues: QRT–PCR analysis of mRNA levels for Runx2 in normal,
CP, and PDAC tissue samples was carried out as described in the Patients and Methods section (box and whiskers graph). RNA input was normalised to the
average expression of the two housekeeping genes HPRT and cyclophilin B, and is presented as transcripts/ml cDNA. (B–H) Runx2 localisation in human
pancreatic tissues: Runx2 immunohistochemistry was performed as described in the Patients and Methods section. Normal pancreatic tissues showing absent
Runx2 staining in the islets (B, white arrowheads), acini, and small ducts (B, white arrows) as well as large ducts (C, d) and endothelial cells (C, white
arrows). (D) Chronic pancreatitis tissues displaying moderate staining in tubular complexes (red asterisks) and degenerating acini. (E–H) Pancreatic cancer
tissues showing moderate Runx2 staining in the cytoplasm of PanIN lesions (E), in the cytoplasm and nuclei of cancer cells using three different Runx2
antibodies (F–H), and fibroblasts (G, inset, white arrows). Note the absent staining in a consecutive tissue section incubated with the corresponding normal
IgG as a negative control (H, inset). Horizontal lines represent the scale bar of 50mm.
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Figure 2 (A and B) Effects of coculture of IPSCs and Panc-1 cells: (A) Cells were cultured in a two-chamber system without cell contact as described in
the Patients and Methods section. Cell lysates were obtained from the cells cultured in the wells and immunoblotting was carried out using a Runx2 antibody
and an ERK2 antibody as a loading control. (B) Cells were cultured alone or cocultured, and immunocytochemistry was performed as described in the
Patients and Methods section. Insets represent negative controls incubated with the corresponding normal IgG. (C) Effects of growth factors and cytokines
on Runx2 mRNA and protein expression in Panc-1 cells and IPSCs: cells were treated with the indicated factors for 48h. Cell lysates were collected for RNA
and protein extraction as described in the Patients and Methods section. Bars represent Runx2 mRNA expression levels as percentage of untreated cellsa s
determined by QRT–PCR. Data are presented as mean±s.e.m. of three independent experiments (*Po0.05). Runt-related transcription factor-2 protein
expression was determined by immunoblotting (first and third panels). Equal loading was determined using a goat polyclonal g-tubulin antibody (second and
fourth panels).
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expression, a significant reduction ( 22.1±2.8%) in MMP1
protein levels was detected in the supernatant of Panc-1 cells
(Figure 4B). Since the basal SPARC mRNA levels were barely
detectable in Panc-1 cells (Figure 3A), the changes in SPARC
protein expression following Runx2 overexpression were not
detectable by immunoblotting (data not shown). IPSCs exhibited
no significant change in MMP1 protein levels by ELISA
(Figure 4B), and SPARC by immunoblotting (data not shown).
In addition, Runx2 silencing led to a significant reduction of SPP
mRNA expression in Panc-1 cells by  33±8.8%, and to a slight
increase of BGLAP mRNA levels by þ5.3±0.4% in IPSCs
(Figure 3B).
Effects of Runx2 on cell morphology, growth, and invasion
of IPSCs and Panc-1 cells
To examine the effects of Runx2 on cell morphology, growth, and
invasion of IPSCs and Panc-1 cells, cytology, growth, and invasion
assays were performed after Runx2 silencing and Runx2 over-
expression. There was no significant change in the cell morphology
of IPSCs and Panc-1 cells (data not shown). Both Panc-1 and IPSCs
also exhibited no significant change in cell growth after Runx2
silencing. In contrast, Runx2 overexpression led to a significant
reduction in cell growth by –22.4±5.4% in Panc-1 cells and
 21.5±3.1% in IPSCs (Figure 4C). In the next set of experiments,
the effects of Runx2 on the invasion of IPSCs and Panc-1 cells were
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Figure 3 (A) mRNA levels of Runx2 and Runx2 target genes in Panc-1 and IPSCs were determined by QRT–PCR as described in the Patients and
Methods section and presented as mean±s.e.m. (n¼3). (B) The effects of Runx2 silencing on the mRNA expression of target genes were determined in
Panc-1 cells and IPSCs by QRT–PCR analysis and presented as mean±s.e.m. (n¼3), compared to control transfected cells. (C) The effects of Runx2
silencing on MMP1 protein levels were determined by an ELISA assay as described in the Patients and Methods section, and presented as mean±s.e.m.
(n¼3) compared to control transfected cells (*Po0.05).
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significant increase in the invasion of Panc-1 cells by
þ195±21% compared to controls (Figure 4D). Immortalised
pancreatic stellate cells exhibited no significant change in cell
invasion after Runx2 silencing. In contrast, Runx2 overexpression
led to a significant reduction in cell invasion of Panc-1 by
 35.1±2.1%, but increased invasion of IPSCs by 43.8±2.3%
(Figure 4D).
DISCUSSION
Runt-related transcription factor-2 expression is deregulated in
many glandular tumours, such as prostate cancer (Brubaker et al,
2003; Pratap et al, 2005) and breast cancer (Barnes et al, 2003).
Runx3, a member of the same family, is overexpressed in bulk
PDAC tissues (Li et al, 2004a), but almost absent in a large group
of cultured pancreatic cancer cell lines due to promoter hyper-
methylation (Wada et al, 2004; Li et al, 2004a). In the present
study, the weak-to-absent Runx2 staining in the normal pancreas
matched the low Runx2 mRNA levels and reflects the homogenous
tissue composition (mainly acinar cells). On the other hand, the
wide range of Runx2 mRNA expression in PDAC and CP reflects
the heterogeneous composition of these tissues, especially of the
Runx2 overexpressing tissue elements such as tubular complexes,
PanIN lesions, and cancer cells (in PDAC tissues). Interestingly,
Runx2 was also localised in the fibroblasts in CP and PDAC, which
is in agreement with the relatively high Runx2 mRNA levels
observed in cultured IPSCs.
The expression of Runx2 in the cancer cells and the associated
stromal fibroblasts in pancreatic cancer tissues prompted us to test
the effects of coculture of IPSCs and Panc-1 cells on Runx2
expression as a naturally occurring process in vivo. Coculture of
both cell lines without a direct cell-to-cell contact led to increased
Runx2 expression in pancreatic cancer cells. In contrast Panc-1
cells decreased Runx2 expression in IPSCs. To identify the factors
responsible for these effects, various growth factors and cytokines
were analysed. Among the analysed factors BMP2 increased Runx2
mRNA levels in Panc-1 cells and both BMP2 and TGF-b1 increased
Runx2 protein levels in the same cell line. In contrast, BMP2 and
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Figure 4 (A and B) Panc-1 cells and IPSCs were transiently transfected with a full-length Runx2 expression vector or an empty control vector. (A)
Immunoblot analysis of control-transfected ( ) and Runx2 transfected (þ) cells was carried out as described in the Patients and Methods section. An ERK2
antibody was used as a loading control. (B) MMP1 levels in Runx2 transfected Panc-1 cells and IPSCs were determined using an ELISA assay and are
presented as mean±s.e.m. (n¼3) compared to control transfected cells. (C and D) The effects of Runx2 silencing (left panel) and Runx2 overexpression
(right panel) on cell growth (C) and cell invasion (D) were determined as described in the Patients and Methods section and are presented as mean±s.e.m.
(n¼3) compared to the respective controls (*Po0.05; **Po0.005).
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apparent effects on Runx2 protein levels. The reasons for the
divergent response with respect to Runx2 mRNA and protein levels
are not known. However, it has been shown that Runx2 expression
can be modulated in several ways, including direct stimulation of
gene expression, post-translational modification, and protein–
protein interactions (Li et al, 2004b; Bae and Lee, 2006; Shen et al,
2006). It is known that Runx2 mRNA can be translated by cap-
dependent and cap independent internal ribosomal entry site
(IRES) mechanisms (Xiao et al, 2003; Elango et al, 2006; Nishio
et al, 2006). IRES-dependent translation adds an additional level at
which expression of this gene is regulated. The two translational
mechanisms can provide the flexibility needed for production of
the protein in the appropriate amount at the proper time and in
the right cell type as has been shown for Runx1 (Pozner et al, 2000;
Levanon and Groner, 2004). Therefore, Runx2 translation through
different mechanisms might explain the discrepancy between
Runx2 protein and mRNA expression levels after TGF-b1 or BMP2
treatment. Irrespectively, our results show that cancer and/or
stromal cells-derived factors like TGF-b1 and BMP2 have the
capacity to modulate Runx2 expression in pancreatic cancer and
stellate cells in an autocrine/paracrine fashion.
Interestingly, forced Runx2 overexpression in Panc-1 cells
reduced cell growth and invasion, whereas Runx2 silencing
increased invasiveness in this cell line. It is therefore tempting to
speculate that Runx2 – induced via paracrine effects of the
activated stroma – functions as tumour suppressive. This is also
indirectly supported by the observation that FGF2 and Shh, which
are known to increase pancreatic cancer cell growth and invasion
(Kornmann et al, 1998; Thayer et al, 2003), led to reduction of
Runx2 mRNA expression in Panc-1 pancreatic cancer cells. In
contrast, Runx2 silencing did not affect growth or invasion of
IPSCs, likely because of the low efficiency of Runx2 silencing in
this cell line. However, Runx2 overexpression led to reduced
growth but increased invasion of IPSCs. This phenomenon has also
been observed in hepatic stellate cells (HSCs) during tissue
remodelling under the effects of another gene, fibroblast activation
protein (FAP) (Wang et al, 2005). Fibroblast activation protein
overexpression in the human HSCs leads to increased cell
adhesion, migration, and invasion. Thus, it might be speculated
that Runx2 facilitates tissue remodelling via direct or indirect
increase in invasion and decrease in the growth of IPSCs, as it has
been suggested for FAP in HSCs (Wang et al, 2005).
The transcriptional activity of Runx2 target genes was studied in
IPSCs and Panc-1 pancreatic cancer cells. In our study, there was
low efficiency of Runx2 silencing, although the current protocol
used for siRNA transfection has been used for other genes
(Berberat et al, 2005; Erkan et al, 2005; Kayed et al, 2005).
Furthermore, two additional Runx2 siRNA sequences were used,
and these exhibited even lower silencing efficiencies than the one
that was used in the final experiments. It is known that the siRNA-
based technology displays a wide range of activities, thus reducing
target mRNA or protein expression by 0–490%. Thus, only a
fraction of siRNAs result in a significant reduction of targets
(Hamada et al, 2002; Holen et al, 2002), which may be due to
several factors. First, the nature of siRNA and the presence of
nucleotide mismatch (Elbashir et al, 2001; Holen et al, 2002;
Amarzguioui et al, 2003; Czauderna et al, 2003). Second, extensive
secondary structure in the mRNA, such as the presence of RNA-
associated proteins and the specific subcellular localisation of the
target mRNA that render the transcript inaccessible to siRNA-
incorporated RISC binding (Holen et al, 2002). Third, the turnover
rate of mRNA and the properties of the target cells, such as
variations in transfection efficiency, cell confluence, passage
number, differentiation status, and the toxicity of the transfection
reagents, all play a role in determining the outcome of gene
silencing by siRNA (Hu et al, 2004).
Despite the relatively low efficiency of Runx2 silencing in the
tested cell lines, there was a significant change in the expression of
several target genes such as SPARC and MMP1 in IPSCs and Panc-
1 pancreatic cancer cells. SPARC is markedly overexpressed and
localised in fibroblasts and extracellular matrix surrounding
tumour cells in PDAC, and increases the invasiveness of pancreatic
cancer cells (Guweidhi et al, 2005). Additionally, SPARC enhances
pancreatic tumour growth in SPARC-null mice, where it is
associated with decreased deposition of extracellular matrix and
reduced cancer cell apoptosis (Puolakkainen et al, 2004). Runt-
related transcription factor-2 silencing increased SPARC levels in
Panc-1 cells. Therefore, the observed low-to-absent SPARC
expression levels in some pancreatic cancer cells in vivo might
be due to suppressive effects of Runx2. Since SPARC is thought to
act as a tumour promoter, these findings point again to Runx2 as a
potential tumour suppressor. In line with these findings, Runx2
silencing also increased the release of MMP1 from Panc-1 cells,
whereas Runx2 overexpression decreased MMP1 levels in the same
cell line. These data are in agreement with the known tumour
suppressor function of members of the Runt family of transcrip-
tion factors. Thus, Runx2 and Runx3 might act as tumour
suppressors in malignant melanoma (Martinez et al, 2005), and
Runx3 in breast, gastric, colon, and hepatocellular carcinomas, as
well as non-small cell lung cancer (Goel et al, 2004; Sakakura et al,
2005; Lau et al, 2006; Miyagawa et al, 2006; Yanagawa et al, 2007).
The reason why the potential tumour suppressor Runx2 is
overexpressed in some pancreatic cancer tissues is currently not
known, and requires further studies. Interestingly, increased
expression of Runx3 has also been observed in approximately
one-third of pancreatic cancer cases (Li et al, 2004a). It could be
speculated that in the Runx2 or Runx3 overexpressing tumours,
other factors might exert stronger tumour promoting effects, and
thereby mask the tumour suppressive effects of Runx2 or Runx3.
In conclusion, Runx2 is upregulated in a subset of PDAC tissues,
both in tumour cells and the associated fibroblasts. Regulation of
Runx2 expression might occur via paracrine mechanisms invol-
ving secretion of growth factors such as TGF-b1, BMP2, and FGF2
and cytokines such as Shh. Runx2 – in turn – suppresses the
transcription of extracellular matrix modulators such as SPARC
and MMP1, and thereby influences the pancreatic cancer micro-
environment.
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